PTC Therapeutics EVP, CLO Mark Elliott Boulding reports $132,809 common stock sale
PTCT•PTC Therapeutics executive Mark Elliott Boulding sold 2,073 common shares on Oct. 5-6 for a reported $132,809. His directly held stake ended unchanged at 105,272 shares.
1. Share sale details
Boulding, PTC Therapeutics’ executive vice president and chief legal officer, sold 2,073 shares at $64.03 each on Oct. 5 and $64.16 each on Oct. 6. The sales followed option exercises for the same number of shares at $39.42 each; his directly held stake ended unchanged at 105,272 shares.
